Jump to content

Anat Ashkenazi

From Wikipedia, the free encyclopedia

Anat Ashkenazi (Hebrew: ענת אשכנזי) is the CFO of Alphabet Inc. and its subsidiary Google. She had previously worked at Eli Lilly and Company since 2001, finishing as CFO there.[1][2][3] Lily's market cap tripled during her three year tenure as CFO.[4] In 2025, Ashkenazi was ranked 51 on a list of most powerful women by Fortune.[5]

Early life and career

[edit]

An Israeli-American,[6][7] Ashkenazi earned a degree in finance and economics from the Hebrew University of Jerusalem and an MBA from Tel Aviv University.[3][7] She worked in the financial services sector in Israel, including for Ma'alot Standard & Poor's and Bank Hapoalim.[3]

Eli Lilly and Company

[edit]

Ashkenazi spent 23 years in Eli Lilly in finance positions for several departments including as CFO of the global oncology division, the global diabetes division and the Lilly Research Laboratories overall, before becoming CFO for Eli Lilly and Company[8][4] During Ashkenazi's tenureship as CFO, Eli Lilly successfully introduced a line of GLP-1 agonists based on tirzepatide under the brand names Mounjaro and Zepbound, which were immensely popular and financially successful.[8][9][10] As CFO, Ashkenazi took steps to massively scale up production of these medications to ensure capacity matched demand.[11][12][13][14][15]

References

[edit]
  1. ^ Broughton, Kristin; Kellaher, Colin. "Google Parent Alphabet Poaches Eli Lilly Finance Chief Ashkenazi". The Wall Street Journal.
  2. ^ Nakrosis, Stephen. "Google's New CFO to Receive $9.9 Million Signing Bonus, $1 Million in Annual Salary". The Wall Street Journal.
  3. ^ a b c Tangalakis-Lippert, Katherine. "Career of Anat Ashkenazi, former Eli Lilly executive turned Google CFO". Business Insider.
  4. ^ a b Bary, Emily (June 5, 2024). "Who is Anat Ashkenazi, the Eli Lilly veteran becoming Google's next CFO?". MarketWatch. Retrieved July 24, 2025.
  5. ^ "Anat Ashkenazi | 2025 Most Powerful Women". Fortune. Retrieved July 24, 2025.
  6. ^ "Israeli woman to lead Google's finance department again". The News of Israel - newsofisrael.com. June 6, 2024. Retrieved June 14, 2024.
  7. ^ a b Calcalist (June 5, 2024). "Israeli-American Anat Ashkenazi appointed CFO of Alphabet". Ynetnews. Retrieved October 29, 2024.
  8. ^ a b Tangalakis-Lippert, Katherine. "Google's new CFO, Anat Ashkenazi, raked in a nearly $10 million signing bonus". Business Insider. Retrieved July 24, 2025.
  9. ^ Elias, Jennifer (June 6, 2024). "Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI". CNBC. Retrieved July 24, 2025.
  10. ^ Constantino, Annika Kim (April 30, 2024). "Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro". CNBC. Retrieved July 24, 2025.
  11. ^ Constantino, Annika Kim (June 17, 2024). "How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi". CNBC. Retrieved July 24, 2025.
  12. ^ Constantino, Annika Kim (May 24, 2024). "Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply". CNBC. Retrieved July 24, 2025.
  13. ^ "Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply through 2024". Yahoo Finance. Archived from the original on February 21, 2024. Retrieved July 24, 2025.
  14. ^ Satija, Bhanvi; Wingrove, Patrick; Satija, Bhanvi (November 2, 2023). "Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist". Reuters. Retrieved July 24, 2025.
  15. ^ Estrada, Sheryl. "How the CFOs of Eli Lilly and Novo Nordisk are coping with 'unprecedented demand' for weight-loss drugs". Fortune. Retrieved July 24, 2025.